All Eyes on Award-Winning MiSight 1 day
2020 Popular Science “Best of What’s New Awards” Recognizes
CooperVision MiSight® 1 Day Contact Lens Innovation
2020 Popular Science “Best of What’s New Awards” Recognizes
CooperVision MiSight® 1 Day Contact Lens Innovation
ROCHESTER, N.Y., December 11, 2020 — CooperVision’s innovative MiSight® 1 day contact lens was recently awarded a 2020 Popular Science “Best of What’s New Award” in the health category. The cornerstone of CooperVision’s Brilliant Futures™ Myopia Management Program, this daily wear, single use contact lens is the first and only FDA-approved* product to slow the progression of myopia (nearsightedness) in age-appropriate children. Slowing the progression of myopia reduces the risk that a child will develop severe heath complications later in life including cataracts, glaucoma, retinal detachment and macular degeneration. [1]
The Popular Science “Best of What’s New Awards” recognize up to 100 of the most innovative technologies from the past year across 10 categories, such as health, home, aerospace and security. Each product or technology must represent a significant step forward in its category. Past award winners have included the first portable defibrillator (1997), NASA’s New Horizons Voyage to Pluto (2015), the first FDA-approved gene therapy (2017) and 5G cellular (2019).
This recognition comes as new data emerges from CooperVision’s landmark clinical study revealing that nearly one in four children’s eyes originally fit with MiSight® 1 day remain stable in their myopia level after six years. [2] The study previously established the lens to be effective in slowing myopia progression in age-appropriate children by an average of 59% over a three-year period, as measured by spherical refraction.†[3]
More than 2,000 U.S. eye care professionals (ECPs) are now certified and able to prescribe CooperVision’s Brilliant Futures™ Myopia Management Program, a figure growing by the day.
Through our work with CooperVision MiSight® 1 day, we’ve seen the award-winning lens go from launch to nationwide availability in just over a year. We look forward to continuing to tell its story, from the science behind its creation to the lives it’s changing every day.
*Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters(spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
† Compared to a single vision 1 day lens over a 3 year period.
[1] Bullimore M. Myopia Control: Why each diopter matters. BCLA 2019 Poster.
[2] Chamberlain P, Arumugam B, Jones D et al. Myopia Progression in Children Wearing Dual-Focus Contact Lenses: 6-Year Findings. Optom Vis Sci 2020;97(E-abstract):200038
[3] Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. Optom Vis Sci. 2019; 96(8):556-67.
The Popular Science “Best of What’s New Awards” recognize up to 100 of the most innovative technologies from the past year across 10 categories, such as health, home, aerospace and security. Each product or technology must represent a significant step forward in its category. Past award winners have included the first portable defibrillator (1997), NASA’s New Horizons Voyage to Pluto (2015), the first FDA-approved gene therapy (2017) and 5G cellular (2019).
This recognition comes as new data emerges from CooperVision’s landmark clinical study revealing that nearly one in four children’s eyes originally fit with MiSight® 1 day remain stable in their myopia level after six years. [2] The study previously established the lens to be effective in slowing myopia progression in age-appropriate children by an average of 59% over a three-year period, as measured by spherical refraction.†[3]
More than 2,000 U.S. eye care professionals (ECPs) are now certified and able to prescribe CooperVision’s Brilliant Futures™ Myopia Management Program, a figure growing by the day.
Through our work with CooperVision MiSight® 1 day, we’ve seen the award-winning lens go from launch to nationwide availability in just over a year. We look forward to continuing to tell its story, from the science behind its creation to the lives it’s changing every day.
*Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters(spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
† Compared to a single vision 1 day lens over a 3 year period.
[1] Bullimore M. Myopia Control: Why each diopter matters. BCLA 2019 Poster.
[2] Chamberlain P, Arumugam B, Jones D et al. Myopia Progression in Children Wearing Dual-Focus Contact Lenses: 6-Year Findings. Optom Vis Sci 2020;97(E-abstract):200038
[3] Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. Optom Vis Sci. 2019; 96(8):556-67.